Skip to main content
Erschienen in: Die Onkologie 11/2019

21.10.2019 | Myelodysplastische Syndrome | Leitthema

Diagnostik und Management des myelodysplastischen Syndroms

verfasst von: Prof. Dr. med. Florian Nolte, Wolf-Karsten Hofmann, Arnold Ganser, Michael Heuser

Erschienen in: Die Onkologie | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die myelodysplastischen Syndrome (MDS) haben in den letzten Jahren eine intensive molekulare Charakterisierung erfahren.

Material und Methoden

Es erfolgte eine Recherche und Bewertung der aktuellen Literatur sowie die Darstellung eigener Erfahrungen.

Ergebnisse

Klinisch relevant ist u. a. die Berücksichtigung der SF3B1-Mutation als Diagnosekriterium innerhalb der WHO-Klassifikation der MDS. Darüber hinaus halten genetische Veränderungen Einzug in das Management von Patienten mit unklaren Zytopenien, in die Differentialdiagnostik, die Prognoseabschätzung und die Einteilung von Grenzbefunden zwischen MDS und myelodysplastische/myeloproliferative Neoplasien oder MDS und akuten myeloischen Leukämien.

Schlussfolgerungen

Einige dieser molekularen Veränderungen dienen als therapeutische Zielstrukturen von Substanzen, die sich zum Teil bereits in klinischer Entwicklung befinden.
Literatur
1.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRef Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRef
2.
Zurück zum Zitat Steensma DP, Bejar R, Jaiswal S et al (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126:9–16CrossRef Steensma DP, Bejar R, Jaiswal S et al (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126:9–16CrossRef
3.
Zurück zum Zitat Heuser M, Thol F, Ganser A (2016) Clonal Hematopoiesis of Indeterminate Potential. Dtsch Arztebl Int 113:317–322PubMedPubMedCentral Heuser M, Thol F, Ganser A (2016) Clonal Hematopoiesis of Indeterminate Potential. Dtsch Arztebl Int 113:317–322PubMedPubMedCentral
4.
Zurück zum Zitat Malcovati L, Galli A, Travaglino E et al (2017) Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 129:3371–3378CrossRef Malcovati L, Galli A, Travaglino E et al (2017) Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 129:3371–3378CrossRef
5.
Zurück zum Zitat Jaiswal S, Natarajan P, Silver AJ et al (2017) Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med 377:111–121CrossRef Jaiswal S, Natarajan P, Silver AJ et al (2017) Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med 377:111–121CrossRef
6.
Zurück zum Zitat Fuster JJ, MacLauchlan S, Zuriaga MA et al (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355:842–847CrossRef Fuster JJ, MacLauchlan S, Zuriaga MA et al (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355:842–847CrossRef
7.
Zurück zum Zitat Coombs CC, Zehir A, Devlin SM et al (2017) Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell 21(e4):374–382CrossRef Coombs CC, Zehir A, Devlin SM et al (2017) Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell 21(e4):374–382CrossRef
8.
Zurück zum Zitat Itzykson R, Kosmider O, Renneville A et al (2013) Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 31:2428–2436CrossRef Itzykson R, Kosmider O, Renneville A et al (2013) Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 31:2428–2436CrossRef
9.
Zurück zum Zitat Jeromin S, Haferlach T, Grossmann V et al (2013) High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica 98:e15–7CrossRef Jeromin S, Haferlach T, Grossmann V et al (2013) High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica 98:e15–7CrossRef
10.
Zurück zum Zitat Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T (2018) The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms. Haematologica 103:e192–e5CrossRef Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T (2018) The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms. Haematologica 103:e192–e5CrossRef
11.
Zurück zum Zitat Maxson JE, Gotlib J, Pollyea DA et al (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368:1781–1790CrossRef Maxson JE, Gotlib J, Pollyea DA et al (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368:1781–1790CrossRef
12.
Zurück zum Zitat Meggendorfer M, Bacher U, Alpermann T et al (2013) SETBP1 mutations occur in 9 % of MDS/MPN and in 4 % of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 27:1852–1860CrossRef Meggendorfer M, Bacher U, Alpermann T et al (2013) SETBP1 mutations occur in 9 % of MDS/MPN and in 4 % of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 27:1852–1860CrossRef
13.
Zurück zum Zitat Schwaab J, Schnittger S, Sotlar K et al (2013) Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 122:2460–2466CrossRef Schwaab J, Schnittger S, Sotlar K et al (2013) Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 122:2460–2466CrossRef
14.
Zurück zum Zitat Lasho TL, Finke CM, Zblewski D et al (2015) Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood Cancer J 5:e275CrossRef Lasho TL, Finke CM, Zblewski D et al (2015) Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood Cancer J 5:e275CrossRef
15.
Zurück zum Zitat Heuser M, Gabdoulline R, Loffeld P et al (2017) Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Ann Hematol 96:1361–1372CrossRef Heuser M, Gabdoulline R, Loffeld P et al (2017) Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Ann Hematol 96:1361–1372CrossRef
16.
Zurück zum Zitat Yoshizato T, Nannya Y, Atsuta Y et al (2017) Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 129:2347–2358CrossRef Yoshizato T, Nannya Y, Atsuta Y et al (2017) Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 129:2347–2358CrossRef
17.
Zurück zum Zitat List AF, Bennett JM, Sekeres MA et al (2014) Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia 28:1033–1040CrossRef List AF, Bennett JM, Sekeres MA et al (2014) Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia 28:1033–1040CrossRef
18.
Zurück zum Zitat Bacher U, Kern W, Alpermann T et al (2011) Prognosis in patients with MDS or AML and bone marrow blasts between 10 % and 30 % is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics. Leukemia 25:1361–1364CrossRef Bacher U, Kern W, Alpermann T et al (2011) Prognosis in patients with MDS or AML and bone marrow blasts between 10 % and 30 % is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics. Leukemia 25:1361–1364CrossRef
19.
Zurück zum Zitat DiNardo CD, Garcia-Manero G, Pierce S et al (2016) Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol 91:227–232CrossRef DiNardo CD, Garcia-Manero G, Pierce S et al (2016) Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol 91:227–232CrossRef
20.
Zurück zum Zitat Lindsley RC, Mar BG, Mazzola E et al (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367–1376CrossRef Lindsley RC, Mar BG, Mazzola E et al (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367–1376CrossRef
21.
Zurück zum Zitat Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465CrossRef Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465CrossRef
22.
Zurück zum Zitat Oliva EN, Alati C, Santini V et al (2017) Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol 4:e127–e36CrossRef Oliva EN, Alati C, Santini V et al (2017) Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol 4:e127–e36CrossRef
23.
Zurück zum Zitat Kantarjian HM, Fenaux P, Sekeres MA et al (2018) Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol 5:e117–e26CrossRef Kantarjian HM, Fenaux P, Sekeres MA et al (2018) Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol 5:e117–e26CrossRef
24.
Zurück zum Zitat Brunner AM, Blonquist TM, Hobbs GS et al (2017) Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv 1:2032–2040CrossRef Brunner AM, Blonquist TM, Hobbs GS et al (2017) Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv 1:2032–2040CrossRef
25.
Zurück zum Zitat Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232CrossRef Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232CrossRef
26.
Zurück zum Zitat Fenaux P, Santini V, Spiriti MAA et al (2018) A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS. Leukemia 32:2648–2658CrossRef Fenaux P, Santini V, Spiriti MAA et al (2018) A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS. Leukemia 32:2648–2658CrossRef
27.
Zurück zum Zitat List A, Dewald G, Bennett J et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456–1465CrossRef List A, Dewald G, Bennett J et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456–1465CrossRef
28.
Zurück zum Zitat Platzbecker U, Germing U, Gotze KS et al (2017) Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 18:1338–1347CrossRef Platzbecker U, Germing U, Gotze KS et al (2017) Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 18:1338–1347CrossRef
29.
Zurück zum Zitat Fenaux PP, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, et al (2018) The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low‑, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood 132(Supplement 1):1CrossRef Fenaux PP, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, et al (2018) The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low‑, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood 132(Supplement 1):1CrossRef
30.
Zurück zum Zitat DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7–17CrossRef DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7–17CrossRef
32.
Zurück zum Zitat Thol F, Weissinger EM, Krauter J et al (2010) IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95:1668–1674CrossRef Thol F, Weissinger EM, Krauter J et al (2010) IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95:1668–1674CrossRef
33.
Zurück zum Zitat Thol F, Damm F, Wagner K et al (2010) Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 116:614–616CrossRef Thol F, Damm F, Wagner K et al (2010) Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 116:614–616CrossRef
34.
Zurück zum Zitat Chaturvedi A, Araujo CMM, Jyotsana N et al (2016) Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2‑hydroxyglutarate. Leukemia 30:1708–1715CrossRef Chaturvedi A, Araujo CMM, Jyotsana N et al (2016) Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2‑hydroxyglutarate. Leukemia 30:1708–1715CrossRef
35.
Zurück zum Zitat Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Swords RT, Roboz GJ et al (2016) Enasidenib (AG-221), Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS). Blood 128(22):343. https://doi.org/10.1182/blood.V128.22.343.343 CrossRef Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Swords RT, Roboz GJ et al (2016) Enasidenib (AG-221), Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS). Blood 128(22):343. https://​doi.​org/​10.​1182/​blood.​V128.​22.​343.​343 CrossRef
36.
Zurück zum Zitat Abou Dalle I, DiNardo CD (2018) The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Ther Adv Hematol 9:163–173CrossRef Abou Dalle I, DiNardo CD (2018) The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Ther Adv Hematol 9:163–173CrossRef
Metadaten
Titel
Diagnostik und Management des myelodysplastischen Syndroms
verfasst von
Prof. Dr. med. Florian Nolte
Wolf-Karsten Hofmann
Arnold Ganser
Michael Heuser
Publikationsdatum
21.10.2019
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 11/2019
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-019-00675-8

Weitere Artikel der Ausgabe 11/2019

Die Onkologie 11/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.